| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 04/01/2004 | WO2004026317A1 Histamine release inhibitor |
| 04/01/2004 | WO2004002399A3 Use of gaba-c receptor antagonists for the treatment of myopia |
| 04/01/2004 | WO2003101932A3 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 04/01/2004 | WO2003099819A3 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics |
| 04/01/2004 | WO2003099284B1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
| 04/01/2004 | WO2003099281A3 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 04/01/2004 | WO2003097597A3 Indole derivatives and the use thereof as cb2 receptor ligands |
| 04/01/2004 | WO2003084943A3 Terphenyl derivatives, preparation thereof, compositions containing same |
| 04/01/2004 | WO2003072029A3 Methods of extending corneal graft survival |
| 04/01/2004 | WO2003070886A3 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
| 04/01/2004 | WO2003009842A8 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 04/01/2004 | WO2002085897A9 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 04/01/2004 | US20040063950 Carbamates derivatived from arylakylamines |
| 04/01/2004 | US20040063946 Jnk inhibitor |
| 04/01/2004 | US20040063944 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| 04/01/2004 | US20040063943 Phosphodiesterase inhibitor; cardiovascular disorders; sexual disorders |
| 04/01/2004 | US20040063791 Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions |
| 04/01/2004 | US20040063785 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 04/01/2004 | US20040063783 Used to treat pathologies characterized by an oxidative stress condition and a lack of availability of endothelial nitrogen monoxide, such as ischemia, restenosis, erectile dysfunction, hypoxia, transplant rejection and diabetes |
| 04/01/2004 | US20040063781 Compounds active at the glucocorticoid receptor II |
| 04/01/2004 | US20040063731 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists |
| 04/01/2004 | US20040063730 Such as 5-(7-(3-chloro-4-methoxybenzylamino-1-methyl-3-propyl-1 H-pyrazolo(4,3-d)pyrimidin-5-yl)pentanoic acid; phosphodiesterase inhibitors; for treatment of cardiovascular disorders, asthma, and allergies; kits |
| 04/01/2004 | US20040063723 One pot synthesis; formylation, oximination, cyanation, saponification and amidation of indole ester |
| 04/01/2004 | US20040063720 Tyrosine kinase inhibitors |
| 04/01/2004 | US20040063717 Employing fatty acid oxidation inhibitor; lowering HbA1c, glucose, total cholesterol and/or triglyceride plasma levels; increasing high density lipoprotein concentration; minimizing side effects; ranolazine |
| 04/01/2004 | US20040063710 Ophthalmological preparations |
| 04/01/2004 | US20040063709 Acute and chronic inflammatory disorders; cancer |
| 04/01/2004 | US20040063707 Azaindole kinase inhibitors |
| 04/01/2004 | US20040063693 5-HT2A receptor related disorders; such as 1-(2-(2-fluoro-4-nitrophenoxy)ethyl)-3-(1piperazinyl)-2(1H)-pyrazinone |
| 04/01/2004 | US20040063689 Compositions containing alpha-2-adrenergic agonist components |
| 04/01/2004 | US20040063688 CCR1 receptor antagonists; such as 5-chloro-2-(2-(-3-(4-fluoro-phenoxy)-8-aza-bicyclo(3.2.1)oct-8-yl)-2-oxo -ethoxy)-benzamide |
| 04/01/2004 | US20040063687 Cardiac arrhythmias; potassium channel function inhibitors; such as 7-(3,4-Dichlorophenyl)-6-(5-fluoro-1-methyl-1H-benzimidazol-2-yl)-4,7 -dihydro-5-(methoxymethyl)pyrazolo-(1,5-a)pyrimidine |
| 04/01/2004 | US20040063674 Tetracycline compounds having target therapeutic activities |
| 04/01/2004 | US20040063661 Treatment of statin side effects |
| 04/01/2004 | US20040063655 Antisense modulation of transforming growth factor-beta expression |
| 04/01/2004 | US20040063644 Urea and urethane derivatives as integrin inhibitors |
| 04/01/2004 | US20040063621 Heterocarpine, a human ghrh-binding protein |
| 04/01/2004 | US20040063607 Process to improve stability of a pharmaceutical composition |
| 04/01/2004 | US20040062825 Remedies for allergic diseases and process for producing the same |
| 04/01/2004 | US20040062819 Insertion catheter into cerebrospinal fluid; administering drug |
| 04/01/2004 | US20040062810 Removal blockage in blood vessels; mixture of angiogenesis inhibitor and polymer |
| 04/01/2004 | US20040061039 Furnace mount and method of installation |
| 04/01/2004 | CA2499859A1 Vitreoretinal tamponades based on fluorosilicone fluids |
| 04/01/2004 | CA2499643A1 Lentiviral vector-mediated gene transfer and uses thereof |
| 04/01/2004 | CA2498662A1 Phenol derivatives and their use as rotamase inhibitors |
| 04/01/2004 | CA2497977A1 Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| 04/01/2004 | CA2497903A1 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient |
| 03/31/2004 | EP1403270A1 Pde iv inhibitors |
| 03/31/2004 | EP1403255A1 Rho KINASE INHIBITORS |
| 03/31/2004 | EP1402888A1 The use of substituted carbocyclic compounds as rotamases inhibitors |
| 03/31/2004 | EP1402266A2 Determination of risk and treatment of complications of prematurity |
| 03/31/2004 | EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 03/31/2004 | EP1401870A2 Antibodies against tumor necrosis factor delta (april) |
| 03/31/2004 | EP1401862A2 Peptide compounds for counteracting reactive oxygen species and free radicals |
| 03/31/2004 | EP1401841A1 Substituted 1-oxa-2,8-diaza-spiro 4,5]dec-2-ene derivatives as medicaments for the treatment of pain |
| 03/31/2004 | EP1401835A1 Carboline derivatives as pde-5 inhibitors |
| 03/31/2004 | EP1401822A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 03/31/2004 | EP1401818A2 Targeted multivalent macromolecules |
| 03/31/2004 | EP1401809A1 Tryptase inhibitors |
| 03/31/2004 | EP1401496A1 Compositions and methods for treating hyperimmune response in the eye |
| 03/31/2004 | EP1401485A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 4-(2- 4-methane sulfonyl oxyphenyl ethoxy)phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and insulin |
| 03/31/2004 | EP1401481A1 Mucosal repair by tff dimer peptides |
| 03/31/2004 | EP1401480A2 Use of endostatin in the treatment of ocular neovascularization |
| 03/31/2004 | EP1401461A2 Selective cox-2 inhibition from edible plant extracts |
| 03/31/2004 | EP1401449A1 Tetracyclic compounds as pde5-inhibitors |
| 03/31/2004 | EP1401444A1 Antihistamines for the treatment of nasal congestion and nasal obstruction |
| 03/31/2004 | EP1401441A2 Allosteric adenosine receptor modulators |
| 03/31/2004 | EP1401435A1 Topical application of thiazolyl amides |
| 03/31/2004 | EP1401415A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 03/31/2004 | EP1401351A2 Method for treating glaucoma vi |
| 03/31/2004 | EP1232174A4 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 03/31/2004 | EP0994705B1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 03/31/2004 | EP0937030B1 3-amino-propoxyphenyl derivatives (i) |
| 03/31/2004 | EP0871439B1 Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds |
| 03/31/2004 | CN1486368A Methods for the production of multimeric proteins, and related compositions |
| 03/31/2004 | CN1486298A Prodrugs of excitatory amino acids |
| 03/31/2004 | CN1486190A Compositions containing an active fraction isolated from scutellariae barbatae and methods of use |
| 03/31/2004 | CN1486188A Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| 03/31/2004 | CN1486187A L-histidine in ophthalmic solutions |
| 03/31/2004 | CN1486186A Improved ophthalmic and contact lens solutions containing forms of vitamin B |
| 03/31/2004 | CN1486178A Histamine receptor antagonists |
| 03/31/2004 | CN1485347A Chitosan derivatives, their preparation and medical composition containing the same as active component |
| 03/31/2004 | CN1143848C 2-arylethyl-(piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists |
| 03/31/2004 | CN1143688C Triacetin as transdermal permeation enhancer |
| 03/31/2004 | CN1143685C Pterygium eliminating liquid |
| 03/31/2004 | CN1143679C Method and material for treating and preventing mucosal tissue inflammation |
| 03/30/2004 | US6713635 As chemical intermediates used for the preparation of s-alpha-ethyl-2-oxo-1-pyrrolidine acetamide |
| 03/30/2004 | US6713508 Such as 7-(3-(3-trifluoromethyl-7-propyl-6-benz-(4,5)-isoxazoloxy)propoxy)-2 -ethylchromane-2-carboxylic acid which are potent agonists of peroxisome proliferator activated receptor |
| 03/30/2004 | US6713498 Method for treating glaucoma VI |
| 03/30/2004 | US6713497 Reducing side effects from excess gamma amino butyric acid (gaba) in central nervous system |
| 03/30/2004 | US6713491 For use as medicine for antagonising the effects of excitatory amino acids upon the nmda receptor complex |
| 03/30/2004 | US6713490 6-(2-(4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl)-1-hydroxy -ethyl)-3,4-dihydro-2(1h)-quinolinone; reduced inhibitory activity at herg (human ether-a-go-go related gene) potassium channel |
| 03/30/2004 | US6713487 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition |
| 03/30/2004 | CA2215470C Heterocyclic diaryl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof |
| 03/25/2004 | WO2004024766A1 Kdr peptides and vaccines containing the same |
| 03/25/2004 | WO2004024717A1 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| 03/25/2004 | WO2004024673A1 Amino-propanol derivatives |
| 03/25/2004 | WO2004024190A2 Recombinant lentivirale vector pseudotyped with the hemagglutinin protein for gene transfer into the retina |
| 03/25/2004 | WO2004024164A1 Stable eye drops containing latanoprost as the active ingredient |
| 03/25/2004 | WO2004013138A3 Imidazo`1,2-a!pyridines |